Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430166 | 0.77 | CYP2B6 (0.32) | — | |
| SCHEMBL1266718 | 0.76 | SMN1; SMN2 (0.35) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL15853682 | 0.75 | CYP2B6 (0.35) | — | |
| SCHEMBL11565244 | 0.73 | MEN1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11565246 | 0.73 | MEN1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL31625697 | 0.73 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL1260778 | 0.72 | SMN1; SMN2 (0.34) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL12509609 | 0.71 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2TSHRMAPK1USP2 | |
| SCHEMBL4471161 | 0.71 | SMN1; SMN2 (0.37) | KMT2AALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL85406 | 0.71 | SMN1; SMN2 (0.37) | KMT2AALDH1A1SMN1; SMN2TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | MEN1 1868/4885KMT2A 1805/4885ALDH1A1 907/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | MEN1 2257/4885KMT2A 3206/4885ALDH1A1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.